Literature DB >> 22261556

Toward a multifactorial model of Alzheimer disease.

Martha Storandt1, Denise Head, Anne M Fagan, David M Holtzman, John C Morris.   

Abstract

Relations among antecedent biomarkers of Alzheimer disease (AD) were evaluated using causal modeling; although correlation cannot be equated to causation, causation does require correlation. Individuals aged 43 to 89 years (N = 220) enrolled as cognitively normal controls in longitudinal studies had clinical and psychometric assessment, structural magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) biomarkers, and brain amyloid imaging via positron emission tomography with Pittsburgh Compound B (PIB) obtained within 1 year. CSF levels of Aβ(42) and tau were minimally correlated, indicating they represent independent processes. Aβ(42), tau, and their interaction explained 60% of the variance in PIB. Effects of APOE genotype and age on PIB were indirect, operating through CSF markers. Only spurious relations via their common relation with age were found between the biomarkers and regional brain volumes or cognition. Hence, at least 2 independent hypothesized processes, one reflected by CSF Aβ(42) and one by CSF tau, contribute to the development of fibrillar amyloid plaques preclinically. The lack of correlation between these 2 processes and brain volume in the regions most often affected in AD suggests the operation of a third process related to brain atrophy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22261556      PMCID: PMC3334456          DOI: 10.1016/j.neurobiolaging.2011.11.029

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  37 in total

1.  Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation.

Authors:  Soyon Hong; Omar Quintero-Monzon; Beth L Ostaszewski; Daniel R Podlisny; William T Cavanaugh; Ting Yang; David M Holtzman; John R Cirrito; Dennis J Selkoe
Journal:  J Neurosci       Date:  2011-11-02       Impact factor: 6.167

2.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

Authors:  Anne M Fagan; Mark A Mintun; Robert H Mach; Sang-Yoon Lee; Carmen S Dence; Aarti R Shah; Gina N LaRossa; Michael L Spinner; William E Klunk; Chester A Mathis; Steven T DeKosky; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

3.  An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest.

Authors:  Rahul S Desikan; Florent Ségonne; Bruce Fischl; Brian T Quinn; Bradford C Dickerson; Deborah Blacker; Randy L Buckner; Anders M Dale; R Paul Maguire; Bradley T Hyman; Marilyn S Albert; Ronald J Killiany
Journal:  Neuroimage       Date:  2006-03-10       Impact factor: 6.556

4.  Screening for dementia by memory testing.

Authors:  E Grober; H Buschke; H Crystal; S Bang; R Dresner
Journal:  Neurology       Date:  1988-06       Impact factor: 9.910

5.  Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease.

Authors:  J L Price; A I Ko; M J Wade; S K Tsou; D W McKeel; J C Morris
Journal:  Arch Neurol       Date:  2001-09

6.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

7.  Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.

Authors:  Trey Sunderland; Nadeem Mirza; Karen T Putnam; Gary Linker; Deepa Bhupali; Rob Durham; Holly Soares; Lida Kimmel; David Friedman; Judy Bergeson; Gyorgy Csako; James A Levy; John J Bartko; Robert M Cohen
Journal:  Biol Psychiatry       Date:  2004-11-01       Impact factor: 13.382

8.  Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype.

Authors:  L Berg; D W McKeel; J P Miller; M Storandt; E H Rubin; J C Morris; J Baty; M Coats; J Norton; A M Goate; J L Price; M Gearing; S S Mirra; A M Saunders
Journal:  Arch Neurol       Date:  1998-03

9.  Distribution volume ratios without blood sampling from graphical analysis of PET data.

Authors:  J Logan; J S Fowler; N D Volkow; G J Wang; Y S Ding; D L Alexoff
Journal:  J Cereb Blood Flow Metab       Date:  1996-09       Impact factor: 6.200

10.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.

Authors:  William E Klunk; Henry Engler; Agneta Nordberg; Yanming Wang; Gunnar Blomqvist; Daniel P Holt; Mats Bergström; Irina Savitcheva; Guo-feng Huang; Sergio Estrada; Birgitta Ausén; Manik L Debnath; Julien Barletta; Julie C Price; Johan Sandell; Brian J Lopresti; Anders Wall; Pernilla Koivisto; Gunnar Antoni; Chester A Mathis; Bengt Långström
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

View more
  28 in total

1.  Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study.

Authors:  Andrew J Aschenbrenner; David A Balota; Anne M Fagan; Janet M Duchek; Tammie L S Benzinger; John C Morris
Journal:  J Int Neuropsychol Soc       Date:  2015-09       Impact factor: 2.892

Review 2.  Biomarkers for the Early Detection and Progression of Alzheimer's Disease.

Authors:  Scott E Counts; Milos D Ikonomovic; Natosha Mercado; Irving E Vega; Elliott J Mufson
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

3.  Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults.

Authors:  Andrew J Aschenbrenner; David A Balota; Chi-Shing Tse; Anne M Fagan; David M Holtzman; Tammie L S Benzinger; John C Morris
Journal:  Neuropsychology       Date:  2014-09-15       Impact factor: 3.295

4.  Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife.

Authors:  Annie M Racine; Rebecca L Koscik; Sara E Berman; Christopher R Nicholas; Lindsay R Clark; Ozioma C Okonkwo; Howard A Rowley; Sanjay Asthana; Barbara B Bendlin; Kaj Blennow; Henrik Zetterberg; Carey E Gleason; Cynthia M Carlsson; Sterling C Johnson
Journal:  Brain       Date:  2016-06-20       Impact factor: 13.501

5.  Clinical and pathologic presentation in Parkinson's disease by apolipoprotein e4 allele status.

Authors:  Sarah E Monsell; Lilah M Besser; Katherine B Heller; Harvey Checkoway; Irene Litvan; Walter A Kukull
Journal:  Parkinsonism Relat Disord       Date:  2014-02-13       Impact factor: 4.891

6.  Brain injury biomarkers are not dependent on β-amyloid in normal elderly.

Authors:  David S Knopman; Clifford R Jack; Heather J Wiste; Stephen D Weigand; Prashanthi Vemuri; Val J Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Michelle M Mielke; Rosebud O Roberts; Bradley F Boeve; Ronald C Petersen
Journal:  Ann Neurol       Date:  2013-02-19       Impact factor: 10.422

Review 7.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

8.  Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals.

Authors:  Miranka Wirth; Cindee M Madison; Gil D Rabinovici; Hwamee Oh; Susan M Landau; William J Jagust
Journal:  J Neurosci       Date:  2013-03-27       Impact factor: 6.167

9.  Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults.

Authors:  Trey Hedden; Elizabeth C Mormino; Rebecca E Amariglio; Alayna P Younger; Aaron P Schultz; J Alex Becker; Randy L Buckner; Keith A Johnson; Reisa A Sperling; Dorene M Rentz
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

10.  Cerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease.

Authors:  Eric McDade; Albert Kim; Jeffrey James; Lei K Sheu; Dora Chieh-Hsin Kuan; Davneet Minhas; Peter J Gianaros; Snezana Ikonomovic; Oscar Lopez; Beth Snitz; Julie Price; Jim Becker; Chet Mathis; William Klunk
Journal:  Neurology       Date:  2014-07-16       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.